International Journal of Molecular Sciences (Nov 2022)

Congenital Stationary Night Blindness: Clinical and Genetic Features

  • Angela H. Kim,
  • Pei-Kang Liu,
  • Yin-Hsi Chang,
  • Eugene Yu-Chuan Kang,
  • Hung-Hsuan Wang,
  • Nelson Chen,
  • Yun-Ju Tseng,
  • Go Hun Seo,
  • Hane Lee,
  • Laura Liu,
  • An-Ning Chao,
  • Kuan-Jen Chen,
  • Yih-Shiou Hwang,
  • Wei-Chi Wu,
  • Chi-Chun Lai,
  • Stephen H. Tsang,
  • Meng-Chang Hsiao,
  • Nan-Kai Wang

DOI
https://doi.org/10.3390/ijms232314965
Journal volume & issue
Vol. 23, no. 23
p. 14965

Abstract

Read online

Congenital stationary night blindness (CSNB) is an inherited retinal disease (IRD) that causes night blindness in childhood with heterogeneous genetic, electrophysical, and clinical characteristics. The development of sequencing technologies and gene therapy have increased the ease and urgency of diagnosing IRDs. This study describes seven Taiwanese patients from six unrelated families examined at a tertiary referral center, diagnosed with CSNB, and confirmed by genetic testing. Complete ophthalmic exams included best corrected visual acuity, retinal imaging, and an electroretinogram. The effects of identified novel variants were predicted using clinical details, protein prediction tools, and conservation scores. One patient had an autosomal dominant CSNB with a RHO variant; five patients had complete CSNB with variants in GRM6, TRPM1, and NYX; and one patient had incomplete CSNB with variants in CACNA1F. The patients had Riggs and Schubert–Bornschein types of CSNB with autosomal dominant, autosomal recessive, and X-linked inheritance patterns. This is the first report of CSNB patients in Taiwan with confirmed genetic testing, providing novel perspectives on molecular etiology and genotype–phenotype correlation of CSNB. Particularly, variants in TRPM1, NYX, and CACNA1F in our patient cohort have not previously been described, although their clinical significance needs further study. Additional study is needed for the genotype–phenotype correlation of different mutations causing CSNB. In addition to genetic etiology, the future of gene therapy for CSNB patients is reviewed and discussed.

Keywords